Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Nat Cancer. 2024 Sep;5(9):1298-1304. doi: 10.1038/s43018-024-00819-9. Epub 2024 Sep 17.
Disease relapse driven by acquired drug resistance limits the effectiveness of most systemic anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has emerged as a potential strategy for enhancing the efficacy and the durability of current therapies. However, barriers remain to implementing persister-directed approaches in the clinic. This Perspective discusses current preclinical and clinical complexities and outlines key steps toward the development of clinical strategies that target therapy-persistent residual disease.
获得性耐药驱动的疾病复发限制了大多数全身性抗癌药物的疗效。在复发前针对残留疾病中的持久性癌细胞进行靶向治疗，已成为提高现有疗法疗效和持久性的潜在策略。然而，在临床上实施针对持久性细胞的方法仍然存在障碍。本文观点讨论了当前临床前和临床的复杂性，并概述了开发针对治疗后持久性残留疾病的临床策略的关键步骤。
